Supplementary Material: Long-term upadacitinib safety in atopic dermatitis stratified by smoking status, oral contraceptive pill use, and cardiovascular risk factors
Description
Long-term upadacitinib safety in atopic dermatitis stratified by smoking status, oral contraceptive pill use, and cardiovascular risk factors
Files
Steps to reproduce
AbbVie is committed to responsible data sharing regarding the studies we sponsor. This includes access to anonymized individual and trial-level data (analysis data sets), as well as other information (eg, protocols, clinical study reports, synopses, or statistical analysis plans), provided the trials are not part of an ongoing or planned regulatory submission. These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided after review and approval of a research proposal, statistical analysis plan, and execution of a data use agreement. Data requests can be submitted at any time after approval in the United States and Europe, and after acceptance of this manuscript for publication. The data will be accessible for 12 months, with possible extensions considered. For more information on the process or to submit a request, visit the following link: https://vivli.org/ourmember/abbvie/, then select “Home.” Individual patient-level data from Optum CDM cannot be shared with third parties under the data use agreement in place between Optum, Inc. and AbbVie, Inc. However, this data source may be accessed by other investigators through their own data use agreements.
Institutions
- AbbVie (United States)Illinois, North Chicago
Categories
Funders
- AbbVie (United States)North Chicago